中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (8): 717-727.doi: 10.35541/cjd.20250488
《脓疱型银屑病诊疗中国专家共识（2026版）》编写委员会专家组
收稿日期:2025-09-08
修回日期:2026-04-20
发布日期:2026-08-03
通讯作者:
史玉玲；顾军；郑志忠
E-mail:shiyuling1973@tongji.edu.cn;gujun79@163.com; zhengzhizhong@medmail.com
基金资助:Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition）”
Received:2025-09-08
Revised:2026-04-20
Published:2026-08-03
Contact:
Shi Yuling; Gu Jun; Zheng Zhizhong
E-mail:shiyuling1973@tongji.edu.cn;gujun79@163.com; zhengzhizhong@medmail.com
Supported by:摘要： 【摘要】 脓疱型银屑病是银屑病的特殊类型，临床表现以红斑基础上的无菌性脓疱为特征，病因涉及遗传、免疫及感染等多种因素。脓疱型银屑病分为局限性和泛发性两个亚型。局限性脓疱型银屑病以外用药物治疗为主，疗效欠佳者可采用系统治疗和物理治疗等；泛发性脓疱型银屑病通常需要系统治疗，可联合外用药物治疗和物理治疗等。本版共识编写委员会专家组在国内外最新指南及《脓疱型银屑病诊疗中国专家共识（2022版）》的基础上，结合我国的诊疗现状，重点在脓疱型银屑病的临床表现及分型、辅助检查、诊断标准和治疗等方面形成了2026版共识，以进一步形成规范化诊疗模式。
《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. [开放获取] 脓疱型银屑病诊疗中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026,59(8):717-727. doi:10.35541/cjd.20250488
Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition）[J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.doi:10.35541/cjd.20250488
| ［1］ | Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis［J］. Expert Rev Clin Immunol, 2019,15（9）:907⁃919. DOI: 10.1080/1744666X.2019.1648209. |
| ［2］ | 张芊, 冯菁楠, 郭金竹, 等. 我国城镇掌跖脓疱病的流行病学特征和经济负担分析［J］. 中华预防医学杂志, 2024,58（5）:642⁃648. DOI: 10.3760/cma.j.cn112150⁃20230814⁃00089. |
| ［3］ | Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background［J］. Acta Derm Venereol, 1996,76（1）:68⁃71. DOI: 10.2340/00015555766871. |
| ［4］ | Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis （Zumbusch）: a French epidemiological survey［J］. Eur J Dermatol, 2006,16（6）:669⁃673. |
| ［5］ | Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in Asia? A population⁃based study using claim data in China and a systematic review［J］. Dermatology, 2023,239（2）:195⁃205. DOI: 10.1159/000528850. |
| ［6］ | 《脓疱型银屑病诊疗中国专家共识（2022版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）［J］. 中华皮肤科杂志, 2022,55（3）:187⁃195. DOI: 10.35541/cjd.20210698. |
| ［7］ | Ayala⁃Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases［J］. Psoriasis （Auckl）, 2016,6:7⁃32. DOI: 10.2147/PTT.S64950. |
| ［8］ | Choon SE, Foley PA, Asawanonda P, et al. Asia⁃Pacific consensus recommendations on the management of generalized pustular psoriasis［J］. J Dermatol, 2024,51（12）:1579⁃1595. DOI: 10.1111/1346⁃8138.17471. |
| ［9］ | Sugiura K. Role of interleukin 36 in generalised pustular psoriasis and beyond［J］. Dermatol Ther （Heidelb）, 2022,12（2）:315⁃328. DOI: 10.1007/s13555⁃021⁃00677⁃8. |
| ［10］ | 朱腾, 晋红中. 泛发性脓疱型银屑病的致病易感基因［J］. 协和医学杂志, 2016,7（6）:445⁃449. DOI: 10.3969/j.issn.1674⁃9081.2016.06.009. |
| ［11］ | Li X, Chen M, Fu X, et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris［J］. J Dermatol Sci, 2014,76（2）:132⁃138. DOI: 10.1016/j.jdermsci.2014.08.007. |
| ［12］ | Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin⁃36 signalling in plaque psoriasis and pustular psoriasis［J］. Acta Derm Venereol, 2018,98（1）:5⁃13. DOI: 10.2340/00015555⁃2808. |
| ［13］ | Körber A, Mössner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis［J］. J Invest Dermatol, 2013,133（11）:2634⁃2637. DOI: 10.1038/jid.2013.214. |
| ［14］ | Fu F, Sun Y, Zhao Q, et al. Rare CARD14 missense variants associated with palmoplantar pustulosis （PPP） in the Chinese Han population［J］. Eur J Dermatol, 2019,29（1）:99⁃100. DOI: 10.1684/ejd.2018.3457. |
| ［15］ | Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1792⁃1799. DOI: 10.1111/jdv. 14386. |
| ［16］ | Johnston A, Xing X, Wolterink L, et al. IL⁃1 and IL⁃36 are dominant cytokines in generalized pustular psoriasis［J］. J Allergy Clin Immunol, 2017,140（1）:109⁃120. DOI: 10.1016/j.jaci.2016.08.056. |
| ［17］ | Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis⁃associated IL⁃17A induces and cooperates with IL⁃36 cytokines to control keratinocyte differentiation and function［J］. Sci Rep, 2017,7（1）:15631. DOI: 10.1038/s41598⁃017⁃15892⁃7. |
| ［18］ | Arakawa A, Vollmer S, Besgen P, et al. Unopposed IL⁃36 activity promotes clonal CD4+ T⁃cell responses with IL⁃17A production in generalized pustular psoriasis［J］. J Invest Dermatol, 2018,138（6）:1338⁃1347. DOI: 10.1016/j.jid.2017. 12.024. |
| ［19］ | Brunasso A, Massone C. Recent advances in palmoplantar pustulosis［J］. Fac Rev, 2021,10:62. DOI: 10.12703/r/10⁃62. |
| ［20］ | Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis ⁃ a model disease for specific targeted immunotherapy, systematic review［J］. Exp Dermatol, 2018,27（10）:1067⁃1077. DOI: 10.1111/exd.13699. |
| ［21］ | Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism［J］. J Dermatol Sci, 2020,98（1）:13⁃19. DOI: 10.1016/j.jdermsci.2020. 03.003. |
| ［22］ | 秦万章, 顾军, 王刚等. 银屑病学［M］. 南京: 江苏凤凰科学技术出版社, 2020:293⁃304. |
| ［23］ | Barker JN, Casanova E, Choon SE, et al. Global Delphi consensus on treatment goals for generalized pustular psoriasis［J］. Br J Dermatol, 2025,192（4）:706⁃716. DOI: 10.1093/bjd/ljae491. |
| ［24］ | Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. DOI: 10.1111/1346⁃8138.14523. |
| ［25］ | Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:737⁃752. DOI: 10.1111/jdv.18851. |
| ［26］ | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. DOI: 10.35541/cjd.20190847. |
| ［27］ | Rivera⁃Díaz R, Daudén E, Carrascosa JM, et al. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment［J］. Dermatol Ther （Heidelb）, 2023,13（3）:673⁃688. DOI: 10.1007/s13555⁃022⁃00881⁃0. |
| ［28］ | Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the international psoriasis council［J］. JAMA Dermatol, 2024,160（7）:758⁃768. DOI: 10.1001/jamadermatol.2024.0915. |
| ［29］ | Sugiura K, Nakasuka A, Kono H, et al. Impetigo herpetiformis with IL36RN mutations in a Chinese patient: a founder haplotype of c.115+6T>C in East Asia［J］. J Dermatol Sci, 2015,79（3）:319⁃320. DOI: 10.1016/j.jdermsci.2015.06.003. |
| ［30］ | Sugiura K, Oiso N, Iinuma S, et al. IL36RN mutations underlie impetigo herpetiformis［J］. J Invest Dermatol, 2014,134（9）:2472⁃2474. DOI: 10.1038/jid.2014.177. |
| ［31］ | 中国医师协会皮肤科医师分会儿童学组, 中华医学会皮肤性病学分会银屑病学组. 儿童脓疱型银屑病诊疗中国专家共识（2025版）［J］. 中华皮肤科杂志, 2025,58（4）:297⁃306. DOI: 10.35541/cjd.20240714. |
| ［32］ | Owczarczyk⁃Saczonek A, Znajewska⁃Pander A, Owczarek W, et al. Clinicopathologic retrospective analysis of annular pustular psoriasis［J］. Acta Dermatovenerol Alp Pannonica Adriat, 2018,27（4）:215⁃219. |
| ［33］ | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. DOI: 10.35541/cjd.20220839. |
| ［34］ | Duffin KC, Bachelez H, Mease PJ, et al. Pustular psoriasis and associated musculoskeletal disorders［J］. J Rheumatol Suppl, 2021,97:34⁃38. DOI: 10.3899/jrheum.201673. |
| ［35］ | Armstrong AW, Elston CA, Elewski BE, et al. Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2024,90（4）:727⁃730. DOI: 10.1016/j.jaad.2023.09.080. |
| ［36］ | Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes［J］. J Allergy Clin Immunol, 2019,143（3）:1021⁃1026. DOI: 10.1016/j.jaci. 2018.06.038. |
| ［37］ | Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases［J］. Arch Dermatol, 1991,127（9）:1339⁃1345. |
| ［38］ | Kishimoto M, Taniguchi Y, Tsuji S, et al. SAPHO syndrome and pustulotic arthro⁃osteitis［J］. Mod Rheumatol, 2022,32（4）:665⁃674. DOI: 10.1093/mr/roab103. |
| ［39］ | Burden AD, Bachelez H, Choon SE, et al. The Generalized Pustular Psoriasis Physician Global Assessment （GPPGA） score: online assessment and validation study of a specific measure of GPP disease activity［J］. Br J Dermatol, 2023,189（1）:138⁃140. DOI: 10.1093/bjd/ljad071. |
| ［40］ | Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2001,145（4）:546⁃553. DOI: 10.1046/j.1365⁃2133.2001.04411.x. |
| ［41］ | Burden AD, Choon SE, Gottlieb AB, et al. Clinical disease measures in generalized pustular psoriasis［J］. Am J Clin Dermatol, 2022,23（Suppl 1）:39⁃50. DOI: 10.1007/s40257⁃021⁃00653⁃0. |
| ［42］ | Ibbotson SH. A Perspective on the use of NB⁃UVB phototherapy vs. PUVA photochemotherapy［J］. Front Med （Lausanne）, 2018,5:184. DOI: 10.3389/fmed.2018.00184. |
| ［43］ | Zhang P, Wu MX. A clinical review of phototherapy for psoriasis［J］. Lasers Med Sci, 2018,33（1）:173⁃180. DOI: 10.1007/s10103⁃017⁃2360⁃1. |
| ［44］ | Goldberg DJ, Chwalek J, Hussain M. 308⁃nm Excimer laser treatment of palmoplantar psoriasis［J］. J Cosmet Laser Ther, 2011,13（2）:47⁃49. DOI: 10.3109/14764172.2011.564769. |
| ［45］ | Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2012,67（2）:279⁃288. DOI: 10.1016/j.jaad.2011.01.032. |
| ［46］ | Leong HF, Wang WH, Peng F. Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review［J］. Postepy Dermatol Alergol, 2024,41（3）:262⁃269. DOI: 10.5114/ada.2024.141128. |
| ［47］ | Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti⁃interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（3）:309⁃316. DOI: 10.1001/jamadermatol. 2017.5937. |
| ［48］ | Terui T, Okubo Y, Kobayashi S, et al. Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo⁃controlled study［J］. Am J Clin Dermatol, 2023,24（5）:837⁃847. DOI: 10.1007/s40257⁃023⁃00788⁃2. |
| ［49］ | Okubo Y, Kobayashi S, Murakami M, et al. Efficacy and safety of brodalumab, an anti⁃interleukin⁃17 receptor a monoclonal antibody, for palmoplantar pustulosis: 16⁃week results of a randomized clinical trial［J］. Am J Clin Dermatol, 2024,25（5）:837⁃847. DOI: 10.1007/s40257⁃024⁃00876⁃x. |
| ［50］ | 王娜, 杨青. 阿普米司特治疗掌跖脓疱病一例［J］. 中国麻风皮肤病杂志, 2024,40（8）:565⁃567. DOI: 10.12144/zgmfskin 202408565. |
| ［51］ | De Luca DA, Papara C, Hawro T, et al. Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis［J］. J Dermatolog Treat, 2024,35（1）:2399220. DOI: 10.1080/09546634.2024.2399220. |
| ［52］ | Heidemeyer K, May Lee M, Cazzaniga S, et al. Palmoplantar pustulosis: a systematic review of risk factors and therapies［J］. Psoriasis （Auckl）, 2023,13:33⁃58. DOI: 10.2147/PTT.S400402. |
| ［53］ | Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options［J］. Int J Dermatol, 2011,50（10）:1195⁃1211. DOI: 10.1111/j.1365⁃4632.2011. 04993.x. |
| ［54］ | Descos M, Girard C, Girod M, et al. Acrodermatitis continua of Hallopeau successfully treated with spesolimab［J］. Ann Dermatol Venereol, 2025,152（2）:103347. DOI: 10.1016/j.annder.2025.103347. |
| ［55］ | He Y, Xiong J, Zhang M, et al. Rapid improvement in refractory acrodermatitis continua of Hallopeau with spesolimab injection［J］. Clin Exp Dermatol, 2025,50（3）:668⁃669. DOI: 10.1093/ced/llae443. |
| ［56］ | Morita A, Okubo Y, Imafuku S, et al. Spesolimab, the first⁃in⁃class anti⁃IL⁃36R antibody: from bench to clinic［J］. J Dermatol, 2024,51（11）:1379⁃1391. DOI: 10.1111/1346⁃8138.17449. |
| ［57］ | Elias M, Zhao S, Le HT, et al. IL⁃36 in chronic inflammation and fibrosis ⁃ bridging the gap?［J］. J Clin Invest, 2021,131（2）DOI: 10.1172/JCI144336. |
| ［58］ | Boehringer Ingelheim International GmbH. 佩索利单抗注射液说明书［Z］. 上海: 勃林格殷格翰（中国）投资有限公司, 2025. |
| ［59］ | Boehringer Ingelheim International GmbH. 佩索利单抗注射液(皮下注射）说明书［Z］. 上海: 勃林格殷格翰（中国）投资有限公司, 2025. |
| ［60］ | Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta⁃analysis［J］. Dermatol Ther （Heidelb）, 2023,13（2）:437⁃451. DOI: 10.1007/s13555⁃022⁃00877⁃w. |
| ［61］ | Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis［J］. Expert Opin Drug Saf, 2020,19（8）:969⁃980. DOI: 10.1080/14740338.2020.1785427. |
| ［62］ | Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin⁃1⁃receptor antagonist Anakinra: lack of correlation with IL1RN mutations［J］. Ann Intern Med, 2010,153（1）:66⁃67. DOI: 10.7326/0003⁃4819⁃153⁃1⁃201007060⁃00030. |
| ［63］ | Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real⁃life experience［J］. Ther Adv Chronic Dis, 2018,9（8）:147⁃158. DOI: 10.1177/2040622318772705. |
| ［64］ | Kurizky PS, Ferreira Cde C, Nogueira LS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding［J］. An Bras Dermatol, 2015,90（3）:367⁃375. DOI: 10.1590/abd1806⁃4841.20153113. |
| ［65］ | Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients［J］. Joint Bone Spine, 2016,83（3）:341⁃343. DOI: 10.1016/j.jbspin.2015.07.004. |
| ［66］ | Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor⁃alpha inhibitors during pregnancy among women who delivered live born infants［J］. Pharmacoepidemiol Drug Saf, 2019,28（3）:296⁃304. DOI: 10.1002/pds.4695. |
| ［67］ | Zhang J, Xia P, Wan L, et al. Generalized pustular psoriasis of pregnancy successfully treated with secukinumab［J］. Indian J Dermatol Venereol Leprol, 2023,89（6）:886⁃888. DOI: 10. 25259/IJDVL_1060_2022. |
| ［68］ | Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab［J］. J Dermatol, 2016,43（12）:1439⁃1440. DOI: 10.1111/1346⁃8138.13429. |
| ［69］ | Babuna Kobaner G, Polat Ekinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case［J］. Dermatol Ther, 2020,33（4）:e13571. DOI: 10.1111/dth.13571. |
| ［70］ | Navarini AA, Pagotto A, Langford B, et al. Mortality, prevalence, comorbidity, and flare patterns in generalised pustular psoriasis: a comprehensive literature review［J］. Eur J Dermatol, 2025,35（6）:459⁃470. DOI: 10.1684/ejd.2025.4998. |
| ［71］ | Bachelez H. Pustular Psoriasis: the dawn of a new era［J］. Acta Derm Venereol, 2020,100（3）:adv00034. DOI: 10.2340/00015 555⁃3388. |
| ［72］ | Wang Q, Liu W, Zhang L. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China［J］. An Bras Dermatol, 2017,92（3）:319⁃322. DOI: 10.1590/abd1806⁃4841. 20175536. |
| ［73］ | Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis⁃⁃most common form of pustular psoriasis in children: report of three cases and review of the literature［J］. Pediatr Dermatol, 2002,19（1）:19⁃25. DOI: 10.1046/j.1525⁃1470.2002. 00026.x. |
| ［74］ | Kromer C, Loewe E, Schaarschmidt ML, et al. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients［J］. J Dermatol, 2020,47（9）:989⁃997. DOI: 10.1111/1346⁃8138.15466. |
| [1] | 李燕红 姜琨 吴卓璇 章建兰 方美珍 刘姝婷 王琳琳 胡磊 周小勇 陈柳青 陈金波. 程序性死亡受体1抑制剂相关皮肤不良反应18例临床资料分析[J]. 中华皮肤科杂志, 2026, 59(8): 783-787. |
| [2] | 《西罗莫司治疗卡波西样血管内皮瘤中国专家共识（版）》制订专家组. 西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 728-737. |
| [3] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. 中国皮肤鳞状细胞癌诊疗指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(8): 703-716. |
| [4] | 时熔灿, 余增洋, 罗清琼 马蕊, 蒋星宇, 王媛媛, 蔡江鲁伊, 史玉玲, . 银屑病皮损的棕榈酰化组学特征及其在炎症反应中的作用初探[J]. 中华皮肤科杂志, 2026, 59(8): 738-749. |
| [5] | 魏瑾 闫会文 张建中 伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026, 59(7): 671-674. |
| [6] | 王琳琳 曹立娟 陈柳青 李东升 胡燕燕. 海姆泊芬光动力疗法治疗四肢鲜红斑痣疗效观察及安全性回顾分析[J]. 中华皮肤科杂志, 2026, 59(7): 637-644. |
| [7] | 刘怿菲 金炫沃 刘鹏月 张希萌 吴严. 点阵CO2激光联合A型肉毒毒素外用治疗面部毛孔粗大的半脸自身对照临床试验[J]. 中华皮肤科杂志, 2026, 59(7): 645-653. |
| [8] | 宇文天翊 周子桢 田竞宇 陈思涵 李敏 张峰源 顾恒 陈旭. 角质形成细胞谷氨酰胺酶1/氨代谢轴在中波紫外线诱导的急性损伤和银屑病皮肤炎症中的表达研究[J]. 中华皮肤科杂志, 2026, 59(7): 654-661. |
| [9] | 张国龙 赵子君. 氨基酮戊酸光动力疗法治疗皮肤鳞状细胞癌的现状、挑战和思考[J]. 中华皮肤科杂志, 2026, 59(7): 626-631. |
| [10] | 中国研究型医院学会皮肤科学专业委员会 中国医师协会皮肤科医师分会. [开放获取] 窄谱中波紫外线光疗皮肤科临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 595-610. |
| [11] | 中华医学会皮肤性病学分会光动力治疗研究协作组 中国康复医学会皮肤病康复专业委员会及光动力治疗与康复专业委员会 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法治疗尖锐湿疣的临床应用指南（2026版）[J]. 中华皮肤科杂志, 2026, 59(7): 611-618. |
| [12] | 何庆 张涛 王秀丽 高兴华 陈洪铎 柳敏 齐瑞群. 光线性角化病恶性进展相关生物标志物的研究进展[J]. 中华皮肤科杂志, 2026, 59(7): 687-690. |
| [13] | 李芳 林颖. 头颈部特应性皮炎的诊疗研究进展[J]. 中华皮肤科杂志, 2026, 59(6): 586-590. |
| [14] | 孙松朋 龙俊红 褚洪川 周阳洋 刘甲鑫 刘彦 霍兴霄 陈航 荆涛 高静 王艳逊 王锐 李振宇 张书信. 肤痔清软膏与曲安奈德益康唑乳膏治疗肛周慢性湿疹的临床疗效和安全性：一项多中心、随机、对照、双盲、等效性研究[J]. 中华皮肤科杂志, 2026, 59(6): 564-570. |
| [15] | 中华医学会皮肤性病学分会儿童皮肤病学组 中华医学会儿科学分会皮肤病学组 中国康复医学会皮肤病康复专业委员会儿童学组 中国康复医学会皮肤病康复专业委员会特应性皮炎学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中国医师协会儿科学分会皮肤病学组. [开放获取] 中国儿童特应性皮炎预防、治疗与管理实践共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(6): 487-504. |
|
